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Abstract

Practice Problem: Accidental overdose is a continued concern for those who are prescribed
opioids, and it is essential that healthcare members intensify prevention and response measures
in order to prevent death or misuse from this medication.
PICOT: The PICOT question that guided this project was: “In adult patients at an outpatient
chronic pain management clinic (P), how does development and implementation of a safe opioid
risk-reduction office policy (I), compared to usual practice (C), improve patient rates of naloxone
availability and health literacy (O) over eight weeks (T)?”
Evidence: The CDC’s Guideline for Prescribing Opioids for Chronic Pain, the Surgeon
General’s Advisory on Naloxone and Opioid Overdose, and the U.S Department of Health and
Human Services website were used to gather evidence-based components for information and
practice changes.
Intervention: This project created a safe opioid risk-reduction strategy in the form of a new
office protocol that ensured naloxone was received with instruction on what to do in the event of
an overdose or life-threatening respiratory reaction to opioids and other safety information. The
providers assessed the change in knowledge by using the teach back method.

Outcome: The results showed improvement in the availability of naloxone as a reversal agent as
well as increased understanding of safe opioid storage, disposal, and drug interactions.

Conclusion: The manuscript reports barriers, successes, and challenges discovered during the
project. The recommendations can be applied to other outpatient clinic sites to enhance the safety
of all patients who manage their chronic pain with the use of prescription opioids.
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Development and Implementation of a Safe Opioid Risk-Reduction Strategy
Over the last several years, accidental overdose has become a common cause of
preventable deaths. (Martino et al., 2019). This is a major public health issue. Unfortunately,
both providers and the public lack understanding of the serious risks associated with opioid use
(Agency for Healthcare Research and Quality, 2019).
The Centers for Disease Control and Prevention (CDC) identified patients who had a
greater risk of prescription opioid overdose as “those who were prescribed high daily dosages of
opioids for chronic pain, who concurrently used benzodiazepines with opioids, and/or had a
history of a substance use disorder” (2019, para. 11). Adults with limited health literacy have
difficulty managing their chronic conditions, which leads to greater hospitalization rates and
higher healthcare expenses (Ylitalo et al., 2018). Naloxone hydrochloride is a competitive opioid
antagonist that binds to the mu receptors in the body (CDC, 2019). This medication can rapidly
“reverse the effects of opioids including those associated with overdose such as respiratory
depression” and increased access to naloxone can reduce overdose death by 35-50% (National
Institutes of Health, 2017, U.S Department of Health and Human Services [HHS], 2018a, p.1).
Regrettably, this life-saving medication is not always available during situations when it is
needed the most (CDC, 2019).
This evidenced-based project (EBP) created a safe opioid risk-reduction strategy in the
form of a new office protocol designed to ensure all patients using prescription opioids received
a prescription for naloxone and instruction on what to do in the event of an overdose or lifethreatening respiratory reaction to opioids (Next Harm Reduction, Inc., 2020). For those who
could not afford the medication, a shipment of Narcan was provided to them through a
collaboration with Next Harm Reduction, Inc. (2020). The CDC and The American Society of
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Regional Anesthesia and Pain Medicine (ASRA) recommended patient handouts were also used
to increase understanding of the potential dangers of opioids and reviewed the safe storage,
disposal, tapering medications, and potential interactions with other substances (ASRA, n.d.;
HHS, 2018b). This project reduced the risk of accidental overdose and ensured the safe use of
prescription opioid medication.
Significance of the Practice Problem
During the last 15 years overdoses from synthetic and non-synthetic opioid use have
increased fourfold in the United States (Frieden & Houry, 2016). During the years 1999 to 2017,
nearly 400,000 people died from drug overdoses involving prescription or illicit opioids (CDC,
2020). Nearly 40 percent of those deaths were a direct result of prescription opioid overuse or
misuse. Neville and Foley (2020) reported the total of yearly opioid related deaths outnumbered
the annual mortality rates caused by recent wars, motor vehicle accidents, gun violence, and HIV
combined. The authors argued these deaths were in part a result of increased efforts to improve
pain management, especially since the inception of pain as a fifth vital sign in 1996. Some have
termed this “the biggest public health epidemic of a generation” (Florence et al., 2021, p. 218).
The overdose crisis affects society on all levels. A considerable economic burden has
been triggered by the rise in opioid related morbidity and mortality rates. One estimation is that
the total cost of prescription opioid misuse in the United States is close to 79 billion dollars a
year (CDC, 2019). The combined costs of opioid use disorder and fatal opioid overdose was
estimated to be as high as one trillion dollars in the year 2017 (Florence et al., 2021). These
losses are associated with issues including “premature mortality, criminal justice, childcare and
family assistance, lost productivity, and healthcare services” (Neville & Foley, 2020, p. 10).
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Most of the economic burden, however, can be attributed to loss of life and reduced quality of
living (Florence et al., 2021).
The EBP change clinic is in an urban environment in Southwestern Pennsylvania. On a
statewide level, the prevalence of opioid use disorder was 5.54 per 1,000 commercially insured
residents which totaled almost 40,000 persons in 2016 (Davenport et al., 2019). These figures
accounted for an increased cost of “$16,277 per patient and totals nearly 650 million dollars in
yearly costs” (p. 71). Data from a 2020 analysis indicated this area of Pennsylvania was below
the state average for median household income, median house value, and house age (City Data,
n.d.). The renting percentage and length of stay after moving were also above state average. The
percentage of this population with a bachelor's degree or higher and the number of college
students was below state average. The website states that the percentage of those with a high
school degree or higher was 86.8%, a bachelor’s degree or higher was 12.9%, and those with a
graduate or professional degree was 3.1%. The unemployment rate was 7.8%, which was slightly
higher than the state average of 6.1%.
To curb the increase in prescription opioid overdose rates, several harm reduction
strategies, including use of naloxone for home rescue have been recommended (Dowell et al.,
2016; Frieden & Houry, 2016; Wyse et al., 2018). However, at the clinic where this EBP project
was implemented, even though providers were encouraged to prescribe naloxone, usually in the
form of Narcan, many patients still were not receiving this potentially lifesaving medication.
Identified potential barriers to prescribing naloxone include “stigma toward opioid users, fear of
negative consequences such as increased drug use, time constraints, billing and reimbursement
complications, low self confidence in having discussions with patients, and lack of clinician
education” (Martino et al., 2019, p. 69). There was no formal office protocol or tracking method
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to make sure patients understood the importance of naloxone, how to administer it, or safe
handling of their opioid prescriptions (G. Hites, personal communication, January 11, 2021).
PICOT Question
The PICOT question: “In adult patients at an outpatient chronic pain management clinic
(P), how does development and implementation of a safe opioid risk-reduction office policy (I),
compared to usual practice (C), improve patient rates of naloxone availability and health literacy
(O) over eight weeks (T)?” was created to find the best evidence-based practice literature
available that would support formulation of the project (Echevarria & Walker, 2014).
For this project, the population targeted was adult patients attending an outpatient
interventional pain management clinic, that were aged between eighteen and ninety-nine years
with no defined race or ethnicity. The individual conditions varied, but all participants had a
diagnosis of pain lasting greater than three months and were prescribed opioids to help manage
their chronic pain.
The intervention guided the development and implementation of a safe opioid office
policy. The CDC’s Guideline for Prescribing Opioids for Chronic Pain, the Surgeon General’s
Advisory on Naloxone and Opioid Overdose, and the U.S Department of Health and Human
Services website were used to gather evidence-based components for the information and
practice changes (ASRA, n.d.; Frieden & Houry, 2016; HHS, 2017, 2018b). The carefully
chosen resources were those designed for chronic pain patients regardless of the office settings in
which they presented.
The comparison to usual practice was measured at baseline and post implementation
through the provider checklist, the prescription drug monitoring program (PDMP), and the teachback method. The data evaluations took place in two groups, at baseline and at the four week
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follow up visit. The teach-back method is an “evidence–based, patient-centered intervention that
promotes health literacy, patient engagement and adherence, safety, and quality, using a
universal precaution approach” (Denault et al., 2019, para. 4).
Evidence-Based Practice Framework and Change Theory
This section introduces the framework and change theory models that guided the project
development. Specifically, the Johns Hopkins Nursing Evidence-Based Practice (JHNEBP)
model and Lewin's theory of change were utilized.
Framework
To ensure the appropriate research findings and best practices for this EBP change the
JHNEBP framework was followed (Dang & Dearholt, 2017). This structure employed a threestep process called “PET: practice question, evidence, and translation” (see Appendix A). The
practice question stage consisted of the initial team development, definition of the practice
problem, and finally, identification and meeting with stakeholders and leadership members. In
the evidence stage, quality literature was collected and appraised to determine recommendations
for the project proposal. During the translation stage, synthesized data was funneled into the
final action plan which defined the implementation, evaluation, and dissemination phases of the
EBP project.
Change Theory
To facilitate alterations in behaviors, it was first important to understand the mechanisms
behind the process of change (Lewin, 1951). Lewin's theory of change was used to guide the
desired improvements in self-care behaviors of the patient and the providers during the EBP
change project. Identifying the opposing forces that encourage or hinder change increased the
likelihood of success and sustainability. The terms unfreeze, change, and refreeze are
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characteristics of Lewin’s three-step model reviewed in Figure 1. During this project, the
participant was initially prompted to alter their customary process to overcome their current
behavior (unfreeze). This allowed them to view their typical actions from a different perspective
and to realize the desired transformation (change). Finally, the changes were consistently
implemented, and this behavior became the “new normal” (refreeze). The process concluded
with the integration of the project opioid safety policy components into the standard routine of
the organization for all practice locations in Pennsylvania.
Evidence Search Strategy
To ensure a comprehensive search for strong evidence, relevant literature was initially
identified through an electronic search of databases. The search included the following subject
terms: “chronic pain management,” and “opioid.” This was further investigated with the
expander terms: “safety practices,” “naloxone,” and self-care behaviors.” Databases searched
were: The Cumulative Index to Nursing and Allied Health Literature via smart text searching,
Joanna Briggs Institute EBP, Wolters Kluwer OVID, and Science Direct. Additionally, a
thorough search was made via Google Scholar and Cochrane PICO search engines. This
generated 2,673 articles of possible interest. Duplicate articles were removed and then narrowed
by application of inclusion and exclusion criteria to final number of 14.
Evidence Search Results
The following inclusion criteria were applied to the initial 2,673 literature search results:
(1) adult (<18 years of age), (2) articles published within the last five years, (3) United States
studies, and (4) outpatient setting. This left 362 articles remaining. Articles were then further
eliminated based upon the following exclusion criteria (1) non-English language, (2) non-opioid
management, (3) cancer or palliative care, and (4) secondary sources. Peer-reviewed sources
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chosen were comprised of books, journal articles, published papers and grey literature. Limiters
were added that include “patient safety,” and “education.” These steps yielded 37 articles.
Potential literature was further narrowed by a critical review of abstracts and subject matter was
examined for relevancy. This thorough review ensured the article chosen discussed safety
practices related to chronic pain patients who were prescribed opioids, and that the research
information was appropriate to the EBP change process.
A total of fourteen articles were selected for the literature review, as shown in Figure 2.
The collection included research, systematic reviews, and best practice guidelines. Of the total,
five focused on opioid safety and/or naloxone prescriptions, three related to personal or
organizational health literacy. See articles in Appendix A: Primary Research Review. Two
systematic reviews of literature, listed in Appendix B, related to improved self-care capability.
Four best practice articles supported the use of opioid risk reduction tools, such as those included
in the practice policy for this EBP change and are shown in Appendix C: Consensus Statement
and Guidelines. The underlying goal of increased safe opioid use was evident in each article.
The readings obtained were evaluated and labeled by level and quality using the JHNEBP
model (Dang & Dearholt, 2017, Appendix D). As shown in Table 1, all the articles were rated as
I through V evidence levels and determined to have no less than an A/B rating with the majority
(71%) categorized as high quality- A ranked sources. Therefore, these resources were determined
to be suitable valid research materials that supported the EBP project changes.
Themes with Practice Recommendations
The practice recommendation themes revealed from the final search results are further
examined in this section. Project participants, practice settings, naloxone use, education, and
barriers were analyzed in depth to determine final practice proposals.
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Subjects
All literature study subjects were either adult patients receiving medications classified as
opioids for the purpose of reduction in chronic pain, or practitioners (physicians, pharmacists,
nurse practitioners, and physician assistants) who prescribed opioids and/or educated recipients
on naloxone (Martino et al., 2019; Wyse et al., 2018). Article summaries are provided in
Appendices A and B.
Several studies were conducted at the Department of Veterans Affairs (VA) and the
population was noted to be predominately Caucasian males (Seal et al., 2019; Tiffany et al.,
2015). There were concerns that these results provided an overrepresentation of this
demographic group. However, since this group tends to be most affected by opioid overdose, as
evidenced by Figure 3 and Table 2, the results were determined to be valid. Veterans are part of
the population of patients seen at the EBP change project location which also makes inclusion of
these study results appropriate (G. Hites, personal communication, February 25, 2021). The
study periods ranged from four to 52 weeks in duration.
Practice Setting
All practice study sites were in outpatient facilities except for one meta-analysis and one
research study (Devries et al., 2017; Kadakia et al., 2020). However, all data were applicable to
this EBP change project. It is not necessary to specifically link the impact of opioid-related
education provided by the healthcare provider to a specific setting (Kadakia et al., 2020).
Overall, overdose education and naloxone distribution programs were found to be successful
regardless of the practice location (Devries et al., 2017). For this project, therefore, the
distribution of educational materials and practice guidelines did not require adjustments based on
the project practice specialty or setting.
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Naloxone
Several high-quality studies or practice recommendations focused specifically upon the
reversal agent naloxone as a stand-alone intervention or in conjunction with an overall safety
plan (Devries et al., 2017; HHS, 2018a; Jones et al., 2019; Martino et al., 2019; Seal et al., 2019;
Tiffany et al., 2015). All outcomes showed strong support for increased provider prescribing
habits, improved access to supply, and greater patient knowledge of this medication. Intranasal
use, as opposed to intramuscular injection, was identified as the preferred delivery method. This
was based on patient preference, willingness to administer, safety measures (such as reduced
likelihood for needle stick injuries) and ease of use. The brand name medication, Narcan, was the
most prescribed and used form of naloxone.
Education
Every piece of literature mentioned the impact that education had on reducing opioid risk,
including overdose. Prescription counseling and instruction had a “positive impact on medication
adherence and health outcomes” (Kadakia et al., 2020, p. e32). Several studies utilized targeted
educational methods to increase patient knowledge (Devries et al., 2017; Highland et al., 2020;
Kadakia et al., 2020; Seal et al., 2019). Individual learning styles have become increasingly
dependent on digital technologies so microlearning was noted to be an effective method that
improved health literacy (Wang et al., 2020). Enhanced clinician knowledge of risk reduction
strategies also decreased the potential harm of opioid use for the chronic pain patient (Ducoffe et
al., 2016; HHS, 2018b; Jones et al., 2019; Marszalek et al., 2020; Martino et al., 2019; Wyse et
al., 2018). Comprehension abilities were indicated by the results of patient health literacy
evaluations (Tiffany et al., 2015; Wang et al., 2020; Ziadni et al., 2018). The most effective
delivery methods were video and written education at a third-grade level distributed in a
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collaborative manner (Devries et al., 2017; Frieden & Houry, 2016; Kadakia et al., 2020; Seal et
al., 2019).
From the provider perspective, tools found to reduce the risk of opioid harm included
urine drug tests, state prescription monitoring programs, depression and abuse potential
screening, discussions about medication interactions, safe storage and disposal, and patient
access to an opioid reversal agent in the event of an overdose.
Barriers
Several obstacles to harm reduction health literacy were highlighted in the available
literature. For example, women were noted to have greater difficulty with self-care than men and
patients from low-income populations were less likely to be fully educated on the dangers of
opioids (Ylitalo et al., 2018; Ziadni et al., 2018). Some patients were reluctant to accept a
prescription for naloxone since the risk of overdose was viewed as only for those who “abused”
opioid medications, had an opioid use disorder, or obtained them illegally (Tiffany et al., 2015).
Self-pay or under insured clients had limited access to opioid reversal agents (Devries et al.,
2017; Dowell et al., 2016). Identified barriers for providers included time constraints,
preconceived ideals surrounding opioid use, and lack of knowledge (Martino et al., 2019; Seal et
al., 2019; Wyse et al., 2018).
Recommendation
All articles emphasized the staggering statistics of accidental overdoses associated with
the use of prescription opioids. Death rates are reduced by adopting a combination of
assessments, measures, or actions that emphasize changes within healthcare systems. The
information provided from the literature review acknowledged common problems with chronic
pain patients and offered clinical strategies successful in managing these identified issues.
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Integrating evidenced based changes reduced the risks of death and other harms. In summary, the
EBP project change recommendation to develop and implement a safe opioid risk-reduction
office policy as a strategy to reduce opioid overdose was fully supported by the evidence.
Setting, Stakeholders, and Systems Change
The setting for this project was an outpatient interventional pain management clinic
specializing in managing patients with chronic pain issues through various evaluations and
treatments. This organizational leadership believed in a balanced and multi-disciplinary
approach. Medication management was one of the methods used to improve quality of life and
activities of daily living for patients suffering from chronic pain. They also promoted injection
therapy, chiropractic care, massage, physical therapy, and use of spinal cord stimulators.
Depression is a common co-diagnosis for those with long term health problems, and more than
half of US adults with mental health diagnoses received a prescribed opioid (Rogers et al., 2020).
Recognizing this, the facility evaluated and referred as needed for mood and opioid misuse
disorders.
This site facility was one of eight in Pennsylvania. Physicians, physician assistants, or
nurse practitioner providers rotated to provide patient care at the different locations. A SWOT
analysis was initially created in order to better understand the adjustments needed to successfully
implement the EBP project steps. It was important to evaluate the strategic positioning of the
organization before developing internal strategies. The individual strength, weaknesses,
opportunities, and threats determined are listed in Appendix D.
This micro level practice change project was implemented to directly improve safety
through scripted conversation, process measures, and handouts (Nevis et al., 2008). The
opportunity to increase the safe use of opioids was first identified through conversation with a
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DNP provider who practiced at the location. There was no formal policy in place with set
guidelines or consistency in patient handouts indicating best practice. This project was designed
to ensure continuity of care among providers so that all patients received naloxone with
instruction, and that understanding of this education was demonstrated. The teach-back method
was chosen as an easy method that ensured both parties shared the same information and
increased effective communication of health advice or knowledge (Institute for Healthcare
Improvement Open School [IHI], 2016).
The stakeholders were internal and external members of the organization. Internal patrons
identified were board members, providers, and other employees, such as clerical and clinical
support staff. External participants with a vested interest in the clinic were patients and their
families, insurance companies, pharmaceutical firms, and government. Organizational support
was obtained after meeting with the CEO and the CNO to review key elements of the EBP
change project.
Further collaboration was necessary from the outside agency Next Harm Reduction, an
“online and mail-based harm reduction platform designed to reduce opioid overdose deaths”
(Next Harm Reduction, Inc., 2020, para. 1). This non-for-profit organization was the backup
source of supply for identified patients who could not obtain naloxone through a local pharmacy.
This pilot project was designed to trial at one office with the long-term goal to implement the
policy changes at other sites to create sustainable clinical improvements.
Implementation with Timeline and Budget
The Lewin change theory (1951) guided the development of this project. Driving forces,
that facilitate movement to the desired direction, as well as potential inhibiting forces that pushed
in the opposite direction, were identified as the pilot project was developed.
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Step one, unfreeze (Lewin, 1951), focused on preparing the patient and provider for
changes through staff teaching and online meetings with office staff and providers. The providers
were shown the short video from IHI and given the naloxone handout seen in Appendix E to
encourage understanding of the teach-back method and adherence. The goals of this stage were
to create understanding of why these changes were important and how they would be
accomplished. This built motivation and readiness for patient care. Overcoming the identified
weakness of the organizational resistance to change relied on the strength of the providers
established patient rapport and their willingness to improve the current process. The efforts in
Step One were supported by the administration and expert practitioners who recognized the
importance of this project, as noted in Appendix D.
Step two, change (Lewin, 1951) involved employee efforts to implement the changes as
previously outlined. The project manager (PM) and staff worked together to achieve the desired
outcomes of increased naloxone rates and improved patient safety awareness. The front desk
staff provided the patient information Naloxone/Narcan Safety and Use and Prescription
Opioids: What You Need to Know, listed in Appendix F at the first office visit. The practitioners
instructed the patients who verbally indicated needed assistance to obtain naloxone to the Next
Distro website. A designated laptop was used to allow them to watch the video and register for
home delivery of the reversal agent, as well as an instruction card given so this process could be
completed at home. The conversation guide in Appendix G was used to ensure consistency of
information and facilitated open communication. The PM was to update in office posters with
Narcan or naloxone information as in Appendix H.
Step three, refreezing, accomplished integration of the newly desired behaviors (Lewin,
1951). At the patients four week follow up visit, the provider used the checklist in Appendix I to
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assess understanding of information and confirm naloxone was available to the patient. This
information supported the integration of new practices into the organization, as well as identified
any needed adjustments to the process. Step three implemented effective behaviors and desired
outcomes into the new standard of care and ensured these advances were permanent.
The overall timeframe for the project was eight weeks. The EBP change process and
evaluation occurred after obtaining all required course approvals. The USAHS approval process
was completed by the Evidence-Based Practice Review Council, and email notification was
given prior to implementation. The main project SMART objectives, seen in Appendix J, were as
follows:
1. The PM will develop and implement an evidence-based safe opioid risk-reduction office
policy for adult patients receiving care in an outpatient chronic pain management clinic
by June 1, 2021 (or within 8 weeks of project approval).
2. At the end of the 8-week implementation period, the rate of prescribing provider
adherence to concurrent prescription for naloxone therapy with any opioid prescription
will increase to a rate of 95% or greater.
3. At the end of the 8-week implementation period, the rate of initiation to fill naloxone
therapy via the patient’s pharmacy or Next Distro will increase to a rate of 95% or greater
as determined by provider feedback after they review the PDMP.
4. At the end of the 8-week implementation period, the patient's safe-opioid self-care
behaviors knowledge will increase by 50% or more, post-patient knowledge intervention,
as evidenced by the teach back method.
Appendix J lists team leaders and members involved in the process. A strong understanding of
the underlying objectives was critical to convey the purpose behind these changes to the group.
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Open communication between all members included emails to the staff, and board members. The
PM direct email and phone number was made available to staff for any questions or concerns.
Cost was minimal and met the previously projected amount of less than $100.00. The majority
was spent on educational handout supplies, the actual cost of printing office posters was higher
than anticipated. There were no outside funding sources or additional agency involvement.
Results
The data was collected at the practice site by one provider due to an unexpected change
in staffing. There were no identified HIPAA violations since no records were kept that could
identify specific patients. All information was kept confidential and did not recognize patient
demographic or include any identifying information. All aggregate data was accessible only to
the provider and the PM. The use or disclosure of health information involved no more than a
minimal risk to the privacy of individuals. A binder held all the project forms and was locked in
the providers office. The analysis was done by the PM with the use of the Intellectus Statistics
(2021).
The internally created collection tool in Appendix I was a checklist with face validity and
used to accumulate project information. It is a follow up recommendation that this process
measure tool be revised to simplify further use as there was some confusion on the pre and post
questions. Having the same format for the group one baseline and four-week follow-up group
two will strengthen the integrity of the questionnaire and increase the reliability and validity of
this assessment for future projects.
All established clinic patients were included in the pilot project. No one declined to
participate, all but two were taking opioid prescription medication, and all were English
speaking. There were initially 107 participating patients. Two members no longer qualified at the
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four-week follow up and were removed prior to analysis. The project participants self-identified
gender and method of payment are listed by percentage in Table 3. Thirty-nine persons identified
as male and 68 as female. The most often used payment sources were Medicare and Medicaid.
All categories of measures, benchmarks and statistical tests used to determine the impact
of this EBP change project on increased opioid safety are described in Appendix K. Frequencies
and percentages were calculated for the 107 patients who received the safety packet, NEXT
Distro Narcan information, and were offered a prescription for naloxone at the initial visit at
100%. A majority of the 105 second group participants were able to show knowledge of safeopioid self-care behaviors as assessed by the teach-back method (n = 102, 97%). The above
descriptive data can be seen summarized in Table 4.
A chi-square test of independence was conducted to determine if patients who had
unexpired naloxone were independent variables and presented a change between groups 1 and
group 2 (IS, 2021). The rate of prescribing provider adherence measured before and after project
implementation was determined by the provider checklist. The results of the chi-square test were
not significant based on an alpha value of 0.05, χ2(1) = 2.67, p = .102 as shown in Table 5. This
suggested that the two could be independent of one another and implied that the observed
frequencies were not significantly different than the expected frequencies. It is clinically
significant to note that 102 patients out of 107 (95%) already had an unexpired form of naloxone,
as verified by the PMP, at the beginning of the project evaluation. This showed the providers
were already doing an excellent job of making sure this important reversal agent was available to
their patients who were prescribed opioids.
To examine whether a patient was able to verbalize by the teach back method, how and
when to correctly use naloxone, a chi-square test of independence was conducted on the group 1
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pre and group 2 post implementation data (IS, 2021). These results of the chi-square test were
significant based on an alpha value of 0.05, χ2(1) = 60.89, p < .001. This suggested the education
provided by the practitioner made an impact on an important component of opioid safety. Table
6 presents the results of the chi-square test.
Also of clinical significance is that 34 Narcan devices were attained via the collaboration
between the clinical site and the non-for-profit NEXT Distro organization as shown in Table 4.
This provided supplies for patients who financially were not able to obtain this elsewhere
through their insurance or local pharmacy. Similar resources for additional clinical sites
discovered during this project research were shared with the stakeholders in other states to
further support sustainability.
Any improvement in knowledge that increased the safe use of opioid or naloxone
availability was determined to be clinically significant. The reduced likelihood of death by
overdose was a meaningful clinical change even if not labeled as statistically significant. This
EBP project identified need for a consistent source of education, continued provider
involvement, and sustained future project implementations at other sites. The interventions
effectively impacted the practice concern of opioid safety and risk-reduction that initiated this
project.
Impact
This project was implemented to ensure that a consistent message of safety was presented
to the population of patients who required opioids to help manage their chronic pain. Even
though opioids have an inherent potential to cause harm, they have been shown to provide
effective relief in a certain patient population (Seal et al., 2019; Wyse et al., 2018). Part of the
successful use of these medications includes risk mitigation. The providers involved were willing
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to take on the task of delivering the evidenced based steps of the plan designed with the goal of
increased safe opioid use behaviors. Based on the data collected during the project, the
practitioners were already diligent in ensuring that the reversal agent naloxone was encouraged
and prescribed for their patients. This project increased the availably the reversal medication to
those patients unable to afford it or were hesitant to recognize the importance of proper opioid
storage, disposal, or use. During the previous practice protocol, education was provided, but
usually verbally and there were no designated handouts or method to assess comprehension. The
EBP changes initiated aligned with the practice guidelines from numerous sources such as the
CDC, the U.S. Surgeons General, and the U.S. Department of Health & Human Service InterAgency Task Force as referenced in Appendix C.
Providing practitioner training, as well as patient education, helped alleviate some of the
recognized barriers for naloxone use such as time constraints, preconceived ideals surrounding
opioid use, lack of knowledge, and stigma to having or needing a reversal agent (Martino et al.,
2019; Seal et al., 2019; Wyse et al., 2018). Providers were introduced to the effectiveness and
ease of the teach back method as an educational and evaluation option. This tool can be applied
to other aspects of patient care.
Initially, limitations restricted the accessibility of Narcan at no charge to participants who
resided in Pennsylvania. During the collaboration with the non-for-profit organizations
additional sources were identified that applied to practice sites in other states. This maintains
sustainability of the pilot project and supports continuation at additional locations in Virginia,
New Jersey, and Maryland. The educational components were well received by both the patients,
and stakeholders. They were concluded to be “easy to understand, comprehensive, and
welcomed” (G. Hites, personal communication, September 9, 2021). The posters in Appendix H
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were not implemented due to funding issues during this project but will be utilized at subsequent
practice sites.
Ongoing evaluation for other office sites will be managed by the provider trainers and
individual clinic managers. All resources including patient handouts, provider education, and
project data was given to the organization and distributed based on the initial success of this
project. Only minimal costs are expected for expansion and are mostly for printing costs. The
affordability and simplicity of the project design supports the adaptation of future project
changes.
Dissemination
Within the USAHS facility, a poster board presentation of the EBP change project results
was submitted for review on December 12, 2021. The Third-Party Copyright and SOAR@USA
Electronic Submission Statements were completed, and the final approved manuscript project
was submitted for publishing in the Scholarship and Open Access Repository at USAHS. The
authors updated curriculum vitae includes a link to this work.
The conclusion of this EBP change project was presented to the organizational providers
and staff after receiving final approval for the project report. This was done via an online Power
Point presentation and a copy of the manuscript was emailed to the board members. During the
project, the CEO and CNO, were kept up to date on the progress and findings via email and
informal in person conversations.
To allow for a wider dissemination audience, an abstract was submitted to the American
Society for Pain Management Nursing for consideration of an evidenced-based practice poster
and oral presentation. Journal submissions discussing the practice issue and project findings were
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offered to The Journal of the American Academy of Nurse Practitioners and Pain Management
Nursing.
Conclusion
The EBP change project successfully increased the safe use of prescription opioid
medication and in doing so, reduced the risk of overdose or other harms. This was done through
implementing an office policy that expanded the availability of naloxone, and improved patient,
and provider knowledge. Clinically, this was significant in that the steps taken achieved a
reduction of the likelihood of an accidental overdose or death. This project design can easily be
applied by healthcare practitioners at other outpatient clinic sites to prevent a significant public
health concern. Improvements in health literacy reduce mortality rates as well as the associated
costs and effects of an unintended opioid overdose. Enhanced prevention planning and access to
reversal treatment options protect patients who use prescriptions opioids.
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Table 1
Quality Guide Summary
a:
a/b:
high
high/good
quality quality

evidence
level
I
(4/14)
II
(3/14)
III
(3/14)
IV
(3/14)
V
(1/14)

b:
good
quality

3

1

2

1

1
3
1

2

c:
low
quality

AN OPIOID RISK-REDUCTION STRATEGY

31

Table 2
Drug Overdose Deaths Involving Natural and Semisynthetic Opioids Male/Female Combined
Year

1999 2000 2005 2010 2012 2013 2014 2015 2016

White

2.2

2.3

4.4

8.3

8.2

8.2

8.7

9.0

10.2

Black or
African
American

1.3

1.2

1.9

3.0

3.0

3.5

3.9

4.1

5.3

American
Indian or
Alaska
Native

*

*

4.1

6.4

10.5

7.3

8.2

7.6

7.1

Asian or
Pacific
Islander

*

*

0.3

0.9

0.9

0.8

0.9

0.8

1.1

Hispanic
or Latino

2.6

1.8

2.1

2.4

2.8

3.0

2.8

2.9

3.2

White,
not
Hispanic
or Latino

2.0

2.4

4.9

9.5

9.3

9.4

10

10.6

11.9

Black,
not
Hispanic
or Latino

1.3

1.2

2.0

2.8

3.1

3.3

4

4.3

5.6

Note. * Missing data; Numbers are per 100,000 resident population. Race, gender, year groups
and cause of death involving natural and semisynthetic opioids were used to compile data from
the 1999-2019 CDC Wonder Online Database retrieved January 23, 2021
https://wonder.cdc.gov/controller/datarequest/D76;jsessionid=3222538284C09A233E33AB342F
B4. In the public domain.
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Table 3
Frequency Table for Nominal Variables

Variable
Sex
F
M
Missing
Total
MOP
MD
C
MC
SP
Missing
Total

1

Group
2

Missing

68 (64%)
39 (36%)
0 (0%)
107 (100%)

65 (62%)
40 (38%)
0 (0%)
105* (100%)

0 (0%)
0 (0%)
0 (0%)
0 (100%)

45 (42%)
29 (27%)
32 (30%)
1 (1%)
0 (0%)
107 (100%)

40 (38%)
22 (21%)
43 (41%)
0 (0%)
0 (0%)
105* (100%)

0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (100%)

Note. MOP= method of payment; MD= Medicaid, C= Commercial insurance, MC= Medicare,
SP= Self-pay * Two participants no longer qualified at the four-week follow up.
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Table 4
Frequency Table for Nominal Variables
Variable
Pt received safety pkt.
Y
Missing
Total
Pt. Received NEXT Narcan Info
Y
Missing
Total
Pt offered RX
Y
Missing
Total
NARCAN received from NEXT Distro
N
Y
Missing
Total
Able to TB safe opioid use
Y
N
Missing
Total

1
107 (100%)
0 (0%)
107 (100%)

Group
2
0 (0%)

Missing
0 (0%)
0 (0%)
0 (100%)

107 (100%)
0 (0%)
107 (100%)

0 (0%)
0 (0%)
0 (100%)

107 (100%)
0 (0%)
107 (100%)

0 (0%)
0 (0%)
0 (100%)

Note. Due to rounding error, percentages may not sum to 100%.

71 (68%)
34 (32%)
0 (0%)
105 (100%)

0 (0%)
0 (0%)
0 (0%)
0 (100%)

102 (97%)
3 (3%)
0 (0%)
105 (100%)

0 (0%)
0 (0%)
0 (0%)
0 (100%)
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Table 5
Observed and Expected Frequencies
Group
2

1

2

χ

df

p

Y

102[103.97]

104[102.03]

2.67

1

.102

N

5[3.03]

1[2.97]

Pt. has unexpired naloxone

Note. Pt., patient; Values formatted as Observed [Expected].
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Table 6
Observed and Expected Frequencies
Group
Pt. verbalizes education correctly

1

2

Y

59[82.77]

105[81.23]

N

48[24.23]

0[23.77]

Note. Pt., patient; Values formatted as Observed [Expected].

2

df

p

60.89

1

< .001

χ
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Figure 1
Lewin Change Theory

Note. Figure depicting the stages of Lewin change theory “unfreeze” “change” and “refreeze”.
From Principles of Management, (p. 304), 2012, Saylor Academy.
(https://resources.saylor.org/wwwresources/archived/site/textbooks/Principles%20of%20Manage
ment.pdf). CC BY NC-SA 3.0.
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Figure 2
PRISMA Diagram

Note. Flow of information through the different phases of the EBP Change project literature
search strategy. Adapted from: “Preferred Reporting Items for Systematic Reviews and MetaAnalyses: The PRISMA Statement,” by D. Moher, A. Liberati, J.Tetzlaff, and D. G. Altman,
PLoS Med 6(7): e1000097 (doi:10.1371/journal.pmed1000097). Copyright 2009 by The
PRISMA Group.
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Figure 3
National Overdose Deaths Involving Prescription Opioids

Note. Statistics taken from deaths involving many of the more commonly used drugs available
through 2019. From the 1999-2009 CDC Wonder Online Database, released 12/2020.
(https://www.drugabuse.gov/drug-topics/trends-statistics/overdose-death-rates). In the public
domain.
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Appendix A
Primary Research Review

PICOT EBP QUESTION:
In adult patients at an outpatient chronic pain management clinic (P), how does development and
implementation of a safe opioid risk-reduction office policy (I), compared to usual practice (C),
improve patient rates of naloxone availability and health literacy (O) over four weeks (T)
Articl Author
e
and Date
Numb Published
er
Devries, J.,
et al.
(2017).

Evidence
Type

Sample
Size

Quantitative

Setting
N=252
Naloxone
prescriptions

Quasiexperimental
Study

1.

2.

Highland,
K. B., et al.
(2020).

Quantitative
Quasiexperimental
Study

Large
academic
hospital
healthcare
system

N=152
Patients

Findings Related to
PICOT Question

Measures

Limitations

Evidence
Level
Quality

1. The steady increase in
nalox per month
correlates with increased
provider trainings and
EHR alerts.
2. Source of EHR alerts
and changes
3. Naloxone Prescribing
Guidelines
4. Overdose education
and naloxone distribution
program
checklist
5. Naloxone was
prescribed in response to
13.8% (41/252) of the
EHR alerts
1. Support for and source
of patient, family
member, clinician
educational videos

Nalox by month
compared over 9
months pre- and
post-policy
change.
Demographics of
provider,
department, and
patient
EHR summary
report records

-large, multi-site health
system
- hospital based study
- pharmacist, techs, ER
department and large
education department
staffing

Level II
A

Anonymous
feedback survey
(demographics,
video rating,
educational
approach)

-both pain management
and primary care
settings in militarybased clinics
-pilot study

Level II
A

AN OPIOID RISK-REDUCTION STRATEGY

Marszalek,
D., et al.
(2020).

3.

Quantitative
experimental
Study

N=50
subjects
predominatel
y male and
white/nonHispanic,
with an
average age
(range) of 62
years.

Veterans in
primary care
setting

40
2. Support for and tool
for improved clinical pain
assessment/DVPRS
3. New pain paradigmself-management, opioid
risk mitigation practices
and informed consent
1.Education (via
PowerPoint) that describe
what opioids are and how
to recognize and respond
to an overdose (e.g.,
naloxone education)
2. Statistics re:
unintentional opioid
overdose and how
veterans are particularly
at risk.
3. Medication storage
safety
4. Risks associated with
co-ingesting opioids with
alcohol, other drugs, and
sedating medications (i.e.,
benzodiazepines)

5-point Likert
scale
Three yes/no
assessment
questions

-patient anonymity
prevents follow up

means between
groups (PC-POP
enrollees vs the
comparison group)
and within groups
(PC-POP enrollees
only,
before and after
six months of PCPOP enrollment)
preliminary
independentsamples t tests
utilizing the twotailed significance
test and 95%
confidence
intervals.
generalized linear
modeling (GLM)
and a single
paired-sample t
test (for the
individual
continuous
variable, MEDD)
to examine
whether
differences were

-small sample size
-veterans in
primary care at one
geographical site- lack
of generalizability
-sample of convenience
-mostly male white
patients

Level I
B
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Martino,
J.G., et al.
(2019).

Mixed
methods
Crosssectional
Study

4.

Seal, K. H.,
et al.
(2019)

Mixed
Method;
Explanatory

N= 72
Physicians
and
pharmacists
Large
academic
hospital
healthcare
system
N=100
Patients

Randomized
Controlled
Trial (RTC)

5.

VA primary
care office

41

1. Identification of
barriers to Nalox
2. Support of provider
education and training
specifically regarding
Nalox

1. Support use of
SMART patient goals
2. Internal validity
increased when objective
measures are combined
with clinical measures.
3. Collaborative Care
Model with motivational
interviewing effective
measurement of patient
education
4. Support for and source
of patient-centered
educational materials

statistically
significant before
engagement in the
PC-POP vs post–
PC-POP
engagement
UDS
Questionnaire
Interviews

Current Opioid
Misuse Measure
The Brief Pain
Inventory
The World Health
Organization
Alcohol, Smoking,
and Substance
Involvement
Screening Test
The Pain
Treatment
Satisfaction Scale
The Patient Health
Questionnaire
The Addictions
Behavior
Checklist
Urine Drug Screen

- small study sample
size
-limited to physicians
and pharmacists

Level I
A

-primary care setting
-pilot study
-mostly descriptive
analyses results

Level I
A
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Alcohol
Breathalyzer

Tiffany, E.,
et al.
(2015).

Qualitative
Descriptive
Study

N=90 pts
Veterans
receiving
opioids for
>3 months

6.

Wyse, J. J.,
et al.
(2019).
7.

Qualitative
Descriptive
Study

N= 24
clinicians
Department
of Veterans
Affairs

1. overdose education
and naloxone distribution
OEND programs in the
US helped to rescue more
than
10,000 individuals from
opioid overdoses from
1996 to 2010
2. Veterans surveyed
appeared comfortable
with the idea of
using naloxone kits to
prevent OOD and many
were interested in
receiving a kit.
3. intranasal spray kit
preferred over injection
kit
1. changes to policy and
practice designed to
promote safer prescribing
and patient care
2. recognition of the
harms associated with
long-term opioid therapy
(LTOT)
3. initiatives providers
utilized to meet opioid

Structured 30 min
interview.
DAST-10
AUDIT-C

- sampling
was not randomized.
-pts limited to the VA
-some prior pts in one
group had had previous
opioid education
-93% male pts

Level III
A/B

qualitative content
analysis
AtlasTI, version 7
was used to
organize and code
the data group
coding process,
interviews were
divided and first
coded

-small qualitative
Level III
sample
A/B
obtained through
convenience sampling
methods
-all providers who
participated in the study
were currently
employed within VA
hospitals
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Ziadni, M.,
et al.
(2018)

Quantitative

Multiphasic
RTC Study

8.

Phase I
N=729 clinic
pts
Phase II
N=578 online
pts
N= 145 in
clinic pts
Chronic care
Pts
validation of
the
CARE scale
was
performed in
a tertiary pain
clinic

43
safety requirements and
address common
challenges in caring for
patients.
4. information to
implement new
guidelines.
around opioid
management and
minimize the potential for
patients to experience
opioid-related harms
1. The CARE scale is a
brief, integrated measure
that may be used to reveal
specific interpersonal and
personal impediments to
self-care, and identify
important therapeutic
targets to optimize selfmanagement behaviors

independently and
then exchanged
for secondary
coding

-may be different
regulations based on
State of practice

The Brief Pain
Inventory (BPI)Short Form19
The Patientreported
Outcomes
Measurement
Information
System (PROMIS)
The Pain
Catastrophizing
Scale (PCS)1

-presence of chronic
pain was self-reported
and medical diagnoses
were not confirmed.
-demographics for both
studies revealed that
both
samples were
predominantly female
and middle aged.
-phase I predominantly
Caucasian and college
educated

Level I
A

Note. HER, electronic health records; MEDD, morphine equivalent daily dose; LTOT, long term opioid therapy; Nalox, naloxone
education/prescription; PC-POP, Primary Care Pain Education and Opioid Monitoring Program; PDMP, prescription drug monitoring
program; PTS, patients; UDS, urine drug screen; VA/DoD, Veterans Affairs/Department of Defense
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Appendix B
Systematic Review

PICOT EBP QUESTION:
In adult patients at an outpatient chronic pain management clinic (P), how does development and
implementation of a safe opioid risk-reduction strategy toolkit (I), compared to usual practice (C),
improve health literacy and self-care behaviors (O) over eight weeks (T)
Articl Author and
e
Date
Numb Published
er
Kadakia, N.
N., et al.
(2020).

Evidence
Type

2.

Findings Related
to PICOT
Question

Measures

Limitations

Evidence
Level
Quality

1. the results do not
support one method
of pt education as
being superior to
another.
2. Two studies
measured
knowledge of
medication as a
primary outcome.
3. Statistical
significance shown
for improvements
in knowledge
1. Micro learning
interventions using
short videos were
most popular.
2. Studies showed
statistically
significant positive
effect of
microlearning on

Pain selfefficacy
Questionnaire
Prescription
Opioid
Difficulty Scale

- number of included studies
- consistent results and
recommendation
- comprehensive literature
review with reference to
scientific evidence

Level III
A

Self-care
behavioral
changes
Health literacy
score
Wellness score
Healthy
behavior
change.

-one teen study
-only 4 studies contained equal
distribution between gender
groups
- learning was focused on
varied chronic health conditions
-not all US studies
-some studies with high to mod
bias risks

Setting
Qualitative
Synthesis

10 articles

Systematic
Review

Varied
ED, pain
clinic,
primary
care, level
1 trauma
center,
medical
center

Quantitative
Synthesis

26 articles

1.

Wang, C., et
al. (2020).

Sample
Size

Systematic
Review
Varied
Clinical,
university,
community

Level II
B
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, and
department
of
corrections

Note. Pt., patient.

45
improved
knowledge and
health literacy
behaviors

Treatment
adherence
Health product
use and misuse
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Appendix C
Consensus Statement/Guidelines

PICOT EBP QUESTION:
In adult patients at an outpatient chronic pain management clinic (P), how does development and
implementation of a safe opioid risk-reduction strategy toolkit (I), compared to usual practice (C),
improve health literacy and self-care behaviors (O) over eight weeks (T)
Articl Author and
e
Date
Numb Published
er
Dowell, D.,
et al. (2016).

1.

Ducoffe, A.
R., et al.
(2016).

2.

Evidence
Type

Sample
Size
Setting

Findings Related to
PICOT Question

Measures

Limitations

Evidence
Level
Quality

Center for
Disease
Control
and
Prevention

N/A

N/A

N/A

Level IV
A

Guidelines

U.S.

Office of
Disease
Prevention
and Health
Promotion

N/A

1. Supports nalox and
education as a critical
component to stopping
OOD
2. Resources for tool kit
including clinician and pt
education.
3.Includes safe disposal
and usage education
1. Supports nalox and
education as a critical
component to stopping
OOD.
2. Resources for tool kit
including clinician and pt
education.
3.Includes safe disposal
and usage education

N/A

-original report includes
recommendations for
anticoagulants, and diabetes
agents

Level IV
A

The
National
Action
Plan for
Adverse
Drug Event
Prevention

Outpatient
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3.

4.

U.S.
Department
of Health &
Human
Services.
(2019).

U.S.
Department
of Health &
Human
Services.
(2018).

U.S.
Department
of Health
& Human
Service
interagency task
force
Best
practices
US
Surgeons
General

N/A

U.S.

N/A

Advisory
Statement

47
1. Supports nalox and
education as a critical
component to stopping
OOD.
2. Resources for tool kit
including clinician and pt
education.
3.Includes safe disposal
and usage education

N/A

N/A

Level IV
A

1. Supports nalox and
education as a critical
component to stopping
OOD.
2. Resources for tool kit
including clinician and pt
education.

N/A

Mainly addresses nalox
information

Level V
A

U.S.

Note: nalox, naloxone prescription; OOD, opioid overdose
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SWOT Analysis

Strengths
•Subspecialists expertise
•Willingness to improve process
•Good rapport with patients
•Supportive administration

Weaknesses
•New staff
•Time constraints
•Resistance to change

Opportunities
•Political influence
•Culture of safety
•Electronic health records

Threats
•Goverment regulations
•Competing clinics
•Low health literacy
•Attitudes towards opioids
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Appendix E
Provider Teach-Back Method Video

https://youtu.be/bzpJJYF_tKY
Note. Obtained from IHI Open School, Available through open access, no changes made.
Provider Naloxone Handout

Note. From HHS.Gov (https://www.hhs.gov/opioids/sites/default/files/2018-12/naloxone-coprescribing-guidance.pdf). In the public domain.
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Appendix F
Handouts

Note. From the CDC Prescription Opioids: What You Need to Know, no changes made.
(https://www.cdc.gov/drugoverdose/pdf/aha-patient-opioid-factsheet-a.pdf). In the public domain.
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Note. From “How to Use a Naloxone Kit in the Event of an Overdose,” by UC Davis Center for Design and UC Davis Medical Center, 2020.
(https://naloxonesaves.org/wp-content/uploads/sites/19608/2020/02/How-to-Use-Naloxone-Brochure-ALL-formulations2.pdf). CC BY NCND 4.0.
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Appendix G
Provider Information

First OV
“Please read these two handouts before your next visit so we can talk about the information on safer
opioid use and go over any questions you have. We want to be sure every patient understands the risks
to opioid use. We want you and your family to be as safe as possible.” (checkbox)
“I am going to prescribe Narcan for you today. It is very important that anyone who has opioids in the
home have this in case of an emergency. It is like a fire-extinguisher- no one plans on using it but are
glad they have one if needed. Will your insurance pay for this, or do you want to have it shipped to you?
If they already have RX- “please check the expiration date and let us know when it needs to be refilled or
if you felt you would benefit from having an extra one to carry with you I can prescribe that too.”
“Do you feel very comfortable giving someone Narcan and when to use it?” (checkbox)
“There is information on when and how to give Narcan and we can talk about any questions when you
come back.”

Second OV
“I know I gave you 2 papers to read last month. To make sure that I am giving you all the information
that you need what can we talk about so that you are comfortable with how to take and store your
medication? Do you know where you would dispose of your medications if you do not need them
anymore?” (checkbox)
“Do you have Narcan available to you?” Check PDMP and EMR for Narcan filled since the last OV
(checkbox)
If no RX- “I really want to make sure that you have this reversal medication so that you are safe. What
can I do so that we can get it to you?”
“Can you explain to me your understanding of how and when you would give someone Narcan?”
(checkbox)
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Appendix H
Office Posters
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Note. Posters from “Prevent and Protect”- site by: web360 (https://prevent-protect.org/). Copyright © 2021- Customizable posters with a
blank permission to use and adapt any material on the site, in the public domain.
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Appendix I
Provider Checklist

OFFICE VISIT #1

DATE:

Provider initialsYES

The patient
was given the
two project
handouts.
The patient
was offered a
Narcan RX.
The patient
has previously
received
Narcan from a
pharmacy
within the last
year.
Verified from
PDMP/EMR.

NO

N/A

Comments:
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The patient is
going to
receive
Narcan from
NEXT distro
and watch the
video.
The patient
can correctly
verbalize how
and when to
use Narcan.

OFFICE VISIT # 2

DATE:

Provider initialsYES

The patient
verbalizes the
safe opioid
use in teachback format
The patient
has received
Narcan from a
pharmacy.
Verified from
PDMP/EMR

NO

N/A

Comments:
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Or they have
brought it in
to this visit

The patient
received
Narcan from
NEXT distro
Or is pending
shipment
The patient
does not have
Narcan and
was reeducated on
use and
verbalizes
understanding
via teach-back
method
The patient
can correctly
verbalize how
and when to
use Narcan.
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Appendix J

Timeline Chart
Project Title: Development and Implementation of a Safe Opioid Risk-Reduction Office Policy
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Appendix K
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